Thomas A. Puchalski

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Frits van Rhee, Raymond Wong, Nikhil C. Munshi et al. · The Lancet Oncology · 2014 · 420 citations

Medicine, Multicentric Castleman, Scleroderma

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers et al. · Investigational New Drugs · 2012 · 389 citations

Cnto 888, Medicine, Human Monoclonal Antibody +8

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger et al. · Journal of Clinical Oncology · 2007 · 302 citations

Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy

Rocio García‐Carbonero, Jeff Supko, Judith Manola et al. · Journal of Clinical Oncology · 2004 · 292 citations · Full text

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong et al. · Cancer Chemotherapy and Pharmacology · 2013 · 254 citations

Tumor Immunology, Cnto 888, Solid Tumors +9